Scientific Staff

Jai Prakash

dr. Jai Prakash
Dr. Jai Prakash
Associate Professor
Biomaterials Science and Technology- Targeted Therapeutics
MIRA Institute for Biomedical Technology and Technical Medicine
Room no. ZH254
7500AE, Enschede
The Netherlands
Phone: +31534893096


Jai Prakash obtained his PhD (cum laude) in 2006 at pharmacokinetics and drug targeting from the University of Groningen on the topic “Renal-specific delivery of anti-fibrotic agents using lysozyme to treat renal fibrosis”. Thereafter, he worked as a Vice President – Preclinical Research at BiOrion Technologies with a joint position at the University of Groningen. During this period, he developed several products, which are currently in the pipeline of BiOrion. Besides that, he co-supervised PhD students on the topic “hepatic stellate cell targeting of biological and kinase inhibitors to treat liver fibrosis”. In parallel, he set up a new line of research on tumor stroma targeting to develop novel diagnostics and therapeutics for cancer. To gain new knowledge and experience in tumor stroma field, he joined the group of Prof. Arne Östman at Karolinska Institutet in Stockholm by receiving two prestigious grants Swedish Cancer Foundation grant and Marie Curie Career Integration Grant. Shortly, he became Assistant Professor in the Department of Oncology-Pathology of Karolinska Institutet. He also received a Young Researcher Swedish Research Council Project grant to develop new targeted nanotherapeutics against cancer.

In September 2012, he was appointed as Tenure-track Assistant Professor at Targeted Therapeutics section of Biomaterials, Science and Technology, located at the MIRA Institute of Biomedical Technology and Technical Medicine in the University of Twente. He has obtained several grants funded by Swedish Research council, Dutch Kidney Foundation, Phospholipid Research Centre Heidelberg, MIRA Voucher, and STW Take-off grant.

Since 2013, he also holds an Associated Scientist position in the group of Prof. Östman at the Department of Oncology-Pathology, Karolinska Institutet, Sweden.

In 2016, he has founded a UT spin-off ScarTec Therapeutics BV., which aims to develop novel therapeutic technologies for inhibiting scar formation.